InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,468.08
(
-0.09%
)
US TECH 100
19,221.60
(
-0.19%
)
Dow Jones
39,155.11
(
0.05%
)
Brent Oil
84.50
(
-0.60%
)
Bitcoin
63,997.27
(
-1.27%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

gdollasign

Send PM Follow Ignore
Followers 6
Posts 973
Boards Moderated 0
Alias Born 06/08/2010

gdollasign

Re: DonShimoda post# 22158

Friday, 09/21/2012 11:07:19 AM

Friday, September 21, 2012 11:07:19 AM

Post# of 80490
From the Ariad site:

The latest candidate to enter ARIAD’s early-stage pipeline, AP26113, is a unique small-molecule that in preclinical studies has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) AND epidermal growth factor receptor (EGFR).



So Don, why wouldnt you expect EGFR study results?

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up